MannKind (MNKD) Proxy filing summary

Executive summary

• Annual meeting scheduled for May 20, 2026, to be held virtually, with record date March 23, 2026.

• Key business includes election of nine directors, advisory vote on executive compensation, and ratification of Deloitte & Touche LLP as auditor.

• Company focuses on biopharmaceuticals for chronic diseases, with recent product and partnership developments in diabetes and orphan lung diseases.

• Forward-looking statements address governance, compensation, and product pipeline expectations.

Voting matters and shareholder proposals

• Proposals: (1) Elect nine directors for a one-year term; (2) Advisory vote on executive compensation; (3) Ratify Deloitte & Touche LLP as independent auditor for 2026.

• Board unanimously recommends voting FOR all proposals.

• No other matters are expected, but proxies may vote on additional items if raised.

• Shareholder proposals for the 2027 meeting must be submitted by December 8, 2026, for inclusion.

Board of directors and corporate governance

• Board consists of nine members, with seven deemed independent under Nasdaq standards.

• Chair and CEO roles are separated to reinforce board independence.

• Board committees: Audit, Compensation, and Nominating & Corporate Governance, all with independent members.

• Directors are expected to attend meetings; all attended at least 75% of meetings in 2025.

• Stockholders can communicate with the board via formal processes.